Clinical Trial

A Phase 1 Study of KHN702 Tablets in Healthy Subjects

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 1, 2025 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-center, randomized, double-blind, placebo-controlled study divided into a Single Ascending Dose (SAD) stage and a Multiple Ascending Dose (MAD) phase. The primary objective is to evaluate the safety and tolerability of KHN702 tablets in Chinese healthy volunteers（HVs).
Trial Details
NCT Number NCT07044960
Lead Sponsor Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Conditions Healthy
Enrollment 84 participants
Start Date 2025-06-21
Primary Completion 2026-04-01 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-01